Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942	TEVA	Rasagiline formulations of improved content uniformity	Aug, 2027 (4 years from now)
CN101123946B	TEVA	Rasagiline Formulations Of Improved Content Uniformity	Feb, 2026 (3 years from now)
CN101123946A	TEVA	Rasagiline Formulations Of Improved Content Uniformity	Feb, 2026 (3 years from now)
EP1848402B2	TEVA	Rasagiline Formulations Of Improved Content Uniformity	Feb, 2026 (3 years from now)
EP1848402B1	TEVA	Rasagiline Formulations Of Improved Content Uniformity	Feb, 2026 (3 years from now)
EP1848402A1	TEVA	Rasagiline Formulations Of Improved Content Uniformity	Feb, 2026 (3 years from now)
EP1848402A4	TEVA	Rasagiline Formulations Of Improved Content Uniformity	Feb, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834	TEVA	Rasagiline formulations and processes for their preparation	Dec, 2026 (4 years from now)

Drugs and Companies using RASAGILINE MESYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.